Lack of effect of daily N-acetylcysteine supplementation on mutagen sensitivity

Cancer Epidemiology Biomarkers and Prevention

Volumn 5, Issue 11, 1996, Pages 941-944

  Cloos, Jacqueline ^a   Bongers, Vivian ^a,b   Lubsen, Herman ^b   Tobi, Hilde ^b   Braakhuis, Boudewijn J M ^a   Snow, Gordon B ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANTIOXIDANT; BIOLOGICAL MARKER; BLEOMYCIN; MUTAGENIC AGENT; RETINOL PALMITATE;

ADULT; AGED; ARTICLE; CANCER PREVENTION; CANCER SUSCEPTIBILITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG EFFECT; EUROPE; HEAD AND NECK CARCINOMA; HIGH RISK PATIENT; HUMAN; HUMAN CELL; LYMPHOCYTE; MULTICENTER STUDY; MUTAGEN TESTING; NETHERLANDS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECOND CANCER; SQUAMOUS CELL CARCINOMA;

ACETYLCYSTEINE; ADULT; AGED; ANALYSIS OF VARIANCE; ANTICARCINOGENIC AGENTS; ANTIOXIDANTS; CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMANS; MIDDLE AGED; MUTAGENESIS; MUTAGENICITY TESTS; NEOPLASMS, SECOND PRIMARY;

EID: 0029826588     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Franceschi, S., Levi, F., and La Vecchia, C. Decline in 5-year survival rates for cancer of head and neck. Lancet, 340: 47, 1992.
2. Jovanovic, A., Van der Tol, I. G. U., Kostense, P. J., Schulten, E. A. J. H., De Vries, N., Snow, G. B., van der Waal, I. Second respiratory and upper digestive tract cancer. Oral Oncol. Eur. J. Cancer, 30B: 225-229, 1994.
3. Slaughter, D. P., Southwick, H. W., and Smejkel, W. "Field cancerization" in oral stratified squamous epithelium: clinical implications of multicentric origin. Cancer (Phila.), 6: 963-968, 1953.
4. Hittelman, W. N., Lee, J. S., Cheong, N., Shin, D., and Hong, W. K. The chromosome view of "field cancerization" and multistep carcinogenesis. Implications for chemopreventive approaches. In: U. Pastorino and W. K. Hong (eds.), Chemoimmuno Prevention of Cancer, pp. 41-47. Stuttgart, New York: George Thieme, 1991.
5. De Vries, N., van Zandwijk, N., and Pastorino, U. Chemoprevention in the management of oral cancer: EUROSCAN and other studies. Oral Oncol. Eur. J. Cancer, 28B: 153-157, 1992.
6. Lippman, S. M., Spitz, M. R., Trizna, Z., Benner, S. E., and Hong, W. K. Epidemiology, biology, and chemoprevention of aerodigestive cancer. Cancer, 74: 2719-2725, 1994.
7. Cloos, J., Steen, I., Jocnje, H., Ko, J. Y., De Vries, N., van der Sterre, M. L. T., Nauta, J. J. P., Snow, G. B., and Braakhuis, B. J. M. Association between bleomycin genotoxicity and non-constitutional risk factors for head and neck cancer. Cancer Lett., 74: 161-165, 1993.
8. Cloos, J., Braakhuis, B. J. M., Steen, I., Copper, M. P., De Vries, N., Nauta, J. J. P., and Snow, G. B. Increased mutagen sensitivity in head-and-neck squamous-cell carcinoma patients, particularly those with multiple primary tumors. Int. J. Cancer, 56: 816-819, 1994.
9. Spitz, M. R., Hoque, A., Trizna, Z., Schantz, S. P., Amos, C. I., King, T. M., Bondy, M. L., Hong, W. K., and Hsu, T. C. Mutagen sensitivity as a risk factor for second malignant tumors following malignancies of the upper aerodigestive tract. J. Natl. Cancer Inst., 86: 1681-1684, 1994.
10. Cloos, J., Spitz, M. R., Schantz, S. P., Hsu, T. C., Zhang, Z., Tobi, H., Braakhuis, B. J. M., and Snow, G. B. Genetic susceptibility to head and neck squamous cell carcinoma. J. Natl. Cancer Inst., 88: 530-535, 1996.
11. Trizna, Z., Schantz, S. P., Lee, J. J., Spitz, M. R., Goepfert, H., Hsu, T. C., and Hong, W. K. In vitro protective effects of chemopreventive agents against blcomycin-induced genotoxicily in lymphoblastoid cell lines and peripheral blood lymphocytes of head and neck cancer patients. Cancer Detect. Prev., 17: 575-583, 1993.
12. Küçük, Ö., Pung, A., Franke, A. A., Custer, L. J., Wilkens, L. R., Le Marchand, L., Higuchi, C. M., Cooney, V. R., and Hsu, T. C. Correlations between mutagen sensitivity and plasma nutrient levels of healthy individuals. Cancer Epidemiol., Biomarkers & Prev., 4: 217-221, 1995.
13. Bongers, V., De Jong, J., Steen, I., De Vries, N., Bast, A., Snow, G. B., and Braakhuis, B. J. M. Antioxidant-related parameters in patients treated for cancer chemoprevention with N-acetylcysteine. Eur. J. Cancer, 31A: 921-923, 1995.
14. Hsu, T. C, Cherry, L. M., and Samaan, N. A. Differential mutagen susceptibility in cultured lymphocytes of normal individuals and cancer patients. Cancer Genet. Cytogenet., 17: 307-313, 1985.
15. Pendyala, L., and Creaven, P. J. Pharmacokinetic and pharmacodynamic studies of N-acetylcysteine, a potential chemopreventive agent during phase I trial. Cancer Epidemiol., Biomarkers & Prev., 4: 245-252, 1995.
16. Cloos, J., Gille, J. J. P., Steen, I., Lafleur, V. M. V., Retèl, J., Snow, G. B., and Braakhuis, B. J. M. Influence of the antioxidant N-acetylcysteine and its metabolites on damage induced by bleomycin in PM2 bacteriophage DNA. Carcinogenesis, 17: 327-331, 1996.
17. The alpha-tocopherol, beta-carotene cancer prevention study group. The effect of vitamin E and beta-carotene on the incidence of lung cancer and other cancers in male smokers. N. Engl. J. Med., 330: 1029-1035, 1994.